'Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program.
(...)
Roche found the survival data favored the Keytruda regimen at the first interim analysis. The assessment of progression-free survival (PFS) generated a hazard ratio of 1.27.'
#Immunotherapy #Immunology
https://www.fiercebiotech.com/biotech/roche-stops-pivotal-tigit-trial-after-keytruda-lands-knockout-blow-first-attempt